Paul A. Mahon - Apr 17, 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
EVP & GENERAL COUNSEL
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Stock symbol
UTHR
Transactions as of
Apr 17, 2025
Transactions value $
-$1,826,183
Form type
4
Date filed
4/18/2025, 04:31 PM
Previous filing
Apr 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $1.3M +11K +29.91% $117.76 47.8K Apr 17, 2025 Direct F1
transaction UTHR Common Stock Sale -$112K -400 -0.84% $280.35 47.4K Apr 17, 2025 Direct F1, F2
transaction UTHR Common Stock Sale -$570K -2.02K -4.25% $282.92 45.4K Apr 17, 2025 Direct F1, F3
transaction UTHR Common Stock Sale -$1.56M -5.49K -12.1% $283.83 39.9K Apr 17, 2025 Direct F1, F4
transaction UTHR Common Stock Sale -$881K -3.1K -7.76% $284.69 36.8K Apr 17, 2025 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Option Options Exercise $0 -11K -29.73% $0.00 26K Apr 17, 2025 Common Stock 11K $117.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $279.95 to $280.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $282.36 to $283.325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $283.37 to $284.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $284.38 to $285.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.